CompuGroup Medical (COP) Q3 2024 earnings summary

Executive summary

• Leadership transitioned to Professor Dr. Daniel Gotthardt as CEO, emphasizing operational excellence, innovation, and customer centricity.

• AI and cloud-based solutions, including CGM ONE and Stella, were launched to enhance efficiency and customer value.

• Recurring revenues grew 6% year-over-year, now representing 75% of total revenues, offsetting lower one-time revenues due to project delays.

• Operational improvements in service KPIs, employee recruitment, and product innovation have shown early positive results.

• Company maintains strong positions in 19 countries with a diversified healthcare customer base.

Financial highlights

• Q3 2024 revenues were €283 million, down 0.8% year-over-year, mainly due to lower one-time revenues and project delays.

• Recurring revenues increased by 6% to €213 million, now 75% of total revenue.

• Adjusted EBITDA margin decreased to 19%; adjusted EPS at €0.35, both down year-over-year.

• Free cash flow for nine months was €56 million, down from €90 million, but Q3 saw improvement due to better working capital management.

• Net debt increased, reaching €777 million, mainly due to share buyback, acquisition, and higher bank loan utilization.

Outlook and guidance

• 2024 organic revenue guidance: -2% to 0%; adjusted EBITDA: €202–205 million; recurring revenue share expected between 65% and 70%; adjusted EPS: €1.55–1.95; free cash flow: €40–60 million.

• Segment guidance revised: AIS expected to decline, HIS and PCS to grow low to mid-single digits.

• Q4 expected to have several moving parts; revenues and EBITDA likely at lower end of guidance.